Name | Number of supported studies | Average coverage | |
---|---|---|---|
epithelial cell | 7 studies | 35% ± 16% | |
enterocyte | 6 studies | 37% ± 13% | |
epithelial cell of proximal tubule | 5 studies | 62% ± 7% | |
kidney loop of Henle epithelial cell | 4 studies | 23% ± 9% | |
fibroblast | 4 studies | 27% ± 5% | |
hepatocyte | 4 studies | 25% ± 9% | |
progenitor cell | 3 studies | 29% ± 5% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
kidney | 100% | 12484.93 | 89 / 89 | 98% | 137.38 | 883 / 901 |
liver | 98% | 7782.51 | 222 / 226 | 92% | 87.01 | 372 / 406 |
pancreas | 98% | 1042.76 | 320 / 328 | 92% | 34.67 | 164 / 178 |
prostate | 98% | 1767.02 | 241 / 245 | 91% | 33.03 | 457 / 502 |
intestine | 99% | 4371.93 | 960 / 966 | 89% | 46.68 | 470 / 527 |
brain | 98% | 1255.95 | 2587 / 2642 | 89% | 26.13 | 630 / 705 |
breast | 99% | 1319.74 | 453 / 459 | 87% | 60.38 | 973 / 1118 |
adrenal gland | 100% | 3591.32 | 258 / 258 | 81% | 27.88 | 187 / 230 |
stomach | 99% | 2450.94 | 355 / 359 | 81% | 39.89 | 233 / 286 |
thymus | 98% | 1273.26 | 639 / 653 | 81% | 18.30 | 489 / 605 |
lung | 88% | 828.23 | 509 / 578 | 81% | 36.30 | 933 / 1155 |
bladder | 100% | 1138.95 | 21 / 21 | 61% | 23.69 | 309 / 504 |
uterus | 98% | 1145.41 | 167 / 170 | 59% | 19.64 | 271 / 459 |
ovary | 100% | 2630.69 | 180 / 180 | 52% | 13.23 | 225 / 430 |
esophagus | 67% | 613.77 | 969 / 1445 | 68% | 29.49 | 125 / 183 |
muscle | 100% | 7411.91 | 803 / 803 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 100% | 12.65 | 1 / 1 |
adipose | 98% | 1258.43 | 1185 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 96% | 1116.99 | 1280 / 1335 | 0% | 0 | 0 / 0 |
heart | 94% | 1711.40 | 809 / 861 | 0% | 0 | 0 / 0 |
skin | 55% | 731.76 | 1000 / 1809 | 37% | 8.51 | 175 / 472 |
eye | 0% | 0 | 0 / 0 | 71% | 13.13 | 57 / 80 |
tonsil | 0% | 0 | 0 / 0 | 49% | 9.19 | 22 / 45 |
spleen | 42% | 203.02 | 102 / 241 | 0% | 0 | 0 / 0 |
peripheral blood | 23% | 217.34 | 210 / 929 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 7% | 0.79 | 2 / 29 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0006805 | Biological process | xenobiotic metabolic process |
GO_0005829 | Cellular component | cytosol |
GO_0070062 | Cellular component | extracellular exosome |
GO_0016787 | Molecular function | hydrolase activity |
Gene name | CMBL |
Protein name | Carboxymethylenebutenolidase homolog (EC 3.1.-.-) |
Synonyms | |
Description | FUNCTION: Cysteine hydrolase. Can convert the prodrug olmesartan medoxomil into its pharmacologically active metabolite olmerstatan, an angiotensin receptor blocker, in liver and intestine. May also activate beta-lactam antibiotics faropenem medoxomil and lenampicillin. . |
Accessions | ENST00000296658.4 Q96DG6 |